Onesource Specialty Pharma Limited has disclosed that one of its promoter entities has pledged a significant portion of equity shares to meet business requirements. The pharmaceutical company made this announcement through a regulatory filing dated December 18, 2025.

Share Pledge Details

Tenshi Pharmaceuticals Private Limited pledged 20,00,000 equity shares of Onesource Specialty Pharma Limited on December 16, 2025. The pledge was executed to address certain business and operational needs of the promoter entity.

Regulatory Compliance

The disclosure was made in compliance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The company submitted the required Form to both the Bombay Stock Exchange and National Stock Exchange of India.

The filing was signed by Pudhuccode Radhakrishnan Kannan, Director of Tenshi Pharmaceuticals Private Limited, with DIN 03435209.

Company Information

Onesource Specialty Pharma Limited operates in the pharmaceuticals sector with its registered office located in Navi Mumbai, Maharashtra. The company's corporate office is situated in Bangalore, Karnataka.

Tenshi Pharmaceuticals Private Limited, the pledging entity, has its registered office in Bengaluru, Karnataka. The entity operates under CIN: U74999KA2016PTC200180.

This pledge transaction represents a corporate action undertaken by the promoter group to meet specific business requirements while maintaining regulatory compliance and transparency with market participants.

OneSource Specialty Pharma , formerly known as Stelis Biopharma Limited, has reported its financial results for the first quarter of fiscal year 2026, ending June 30, 2025. The company, which operates primarily in the Contract Development and Manufacturing Organization (CDMO) segment for pharmaceutical products, faced challenges but also announced potential strategic moves. Additionally, the company has recently completed a fresh allotment of equity shares under its employee stock option plan.

Financial Performance

OneSource Specialty Pharma reported a consolidated net loss of ₹1.86 million for Q1 FY26, a significant improvement from the loss of ₹55.47 million in the same quarter last year. The company's revenue from operations increased to ₹3,272.70 million, up from ₹2,922.89 million year-over-year, indicating growth in its core business activities.

On a standalone basis, the company posted a profit of ₹248.15 million, a substantial turnaround from a loss of ₹239.66 million in the previous year's quarter. This improvement in standalone performance suggests stronger operational efficiency within the parent company.

Recent Corporate Actions

In the latest corporate development, OneSource Specialty Pharma's Management Committee approved the allotment of 23,000 equity shares under the OneSource ESOP 2021 plan. The allotment was completed on December 09, 2025, with eligible employees exercising their vested options at a premium of ₹277.00 per share.

Consequent to this allotment, the company's paid-up share capital increased from ₹11,45,62,136 to ₹11,45,85,136, comprising 11,45,85,136 equity shares of ₹1.00 each. The newly allotted shares rank pari passu with existing equity shares in all respects.

Strategic Initiatives and Exceptional Items

The company faced exceptional items worth ₹28.70 million related to legal charges from subsidiary litigation regarding Sputnik vaccine matters during Q1 FY26. Despite these challenges, OneSource Specialty Pharma's Board of Directors has given in-principle approval to evaluate potential acquisitions that could expand the company's capabilities and global reach, including a USFDA-approved sterile fill-finish manufacturing facility in Warsaw, Poland, and an integrated carbapenem facility in Vadodara, India.

Outlook

While OneSource Specialty Pharma faces ongoing challenges, including legal issues related to past vaccine projects, the company's improved revenue, strategic acquisition plans, and continued employee engagement through ESOP allotments indicate a focus on growth and expansion in the CDMO space. The potential acquisitions, particularly of USFDA-approved facilities, could significantly enhance the company's capabilities and market position in the pharmaceutical manufacturing sector.